Skip to content
value.today

Clinical Ink, Inc.

Formerly Clinical Ink, LLC

Total raised
$11 M
4 rounds on record
Latest round
$5 M
May 2018
First round on record
Nov 2011
Today
Private
No later event on record

Funding rounds

4 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Clinical Ink, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2018$5 MNo. 4$2 to $10 million

Clinical Ink, Inc.: Raise no. 4, May 2018

Investors in this round

5 investors had bought by the notice of May 18, 2018: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M (amount offered: indefinite)
Smallest investment taken
$2,651
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Edward S. Seguine, Jr. · Executive Officer, Director
  • Matthew LaVern King · Director
  • Michael LaVern Sorensen · Director
  • Richard LaVern Malcolm · Director
  • Roger LaVern Davenport · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Edward S. Seguine, Jr., Ceo. Source: SEC Form D, newest notice filed May 18, 2018. Read the notice at the SEC.

equitySEC
Dec 2017$2 MNo. 3Under $2 million

Clinical Ink, Inc.: Raise no. 3, Dec 2017

Investors in this round

9 investors had bought by the notice of Dec 28, 2017: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $3 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Edward S. Seguine, Jr. · Executive Officer, Director · Chief Executive Officer
  • Scott S. Miltenberger · Executive Officer · Chief Financial Officer
  • Matt S. King · Director
  • Phil S. Waugh · Director
  • Richard S. Malcolm · Director
  • Todd S. Foley · Director
  • Tony S. Rosenberg · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Scott Miltenberger, Chief Financial Officer. Source: SEC Form D, newest notice filed Dec 28, 2017. Read the notice at the SEC.

debt, optionsSEC
Mar 2015$10 MIssued in a merger or acquisition$2 to $10 million

Clinical Ink, Inc.: Private sale, Mar 2015

Investors in this round

21 investors had bought by the notice of Apr 7, 2015: 21 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$10 M of $10 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
$5 million to $25 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Douglas E. Pierce, Jr. · Executive Officer, Director, Promoter
  • Edward S. Seguine · Executive Officer, Director, Promoter
  • Joe RS Schmidt · Executive Officer
  • Ansbert RS Gadicke · Director
  • Brad RS Geesaman · Director
  • Matt RS King · Director
  • Morana RS Jovan-Embiricos · Director
  • Philip RS Waugh, Jr. · Director
  • Robert RS Kniejski · Director
  • Todd RS Foley · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On a merger: “There was a merger of two entities and some stock was issued in connection with the merger. A new round of financing was also obtained in connection with the merger.”

Signed by Douglas E. Pierce, Jr., President. Source: SEC Form D and 1 amendment, newest notice filed Apr 7, 2015. Read the notice at the SEC.

equitySEC
Oct 2013$1 MNo. 2Under $2 million

Clinical Ink, Inc.: Raise no. 2, Oct 2013

Investors in this round

18 investors had bought by the notice of Oct 29, 2013: 17 accredited, 1 not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $4 M offered; $3 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
$1 million to $5 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Douglas E. Pierce, Jr. · Executive Officer, Director, Promoter
  • Edward S. Seguine · Executive Officer, Director, Promoter
  • Philip RS Waugh, Jr. · Director
  • Robert H. Kniejski · Director
  • Stephen H. Coltrin · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Douglas E. Pierce, Jr., President. Source: SEC Form D, newest notice filed Oct 29, 2013. Read the notice at the SEC.

equitySEC
Nov 2011$3 MNo. 1$2 to $10 million

Clinical Ink, Inc.: Raise no. 1, Nov 2011

Investors in this round

9 investors had bought by the notice of Dec 8, 2011: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $4 M offered; $0 M still to sell
Smallest investment taken
$50,000
What was sold
equity
Exemption claimed
  • 06
  • 46
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in North Carolina

People named in the notice

  • Douglas E. Pierce, Jr. · Executive Officer, Director, Promoter
  • Christopher H. Ramm · Director
  • Michael E. Lester · Director
  • Philip RS Waugh, Jr. · Director
  • Edward S. Seguine, Jr. · Promoter

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Douglas E. Pierce, Jr., Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 8, 2011. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Clinical Ink, Inc. chose not to state its revenue in its newest notice of a funding round (May 2018).

    SEC Form D · May 2018

  • Revenue range over time, as stated in its notices: no revenue in 2011; revenue between $1 million and $5 million in 2013; revenue between $5 million and $25 million in 2015.

    SEC Form D (revenue range) · Apr 2015

  • The industry group it chose in its notices: Other.

    SEC Form D · May 2018

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Clinical Ink, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 18 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Clinical Ink, Inc.
NameRoleNamed in
Edward S. Seguine, Jr.Executive officerMay 2018
Scott S. MiltenbergerChief Financial OfficerDec 2017
Douglas E. Pierce, Jr.Executive officerApr 2015
Edward S. SeguineExecutive officerApr 2015
Joe RS SchmidtExecutive officerApr 2015
Edward S. Seguine, Jr.DirectorMay 2018
Matthew LaVern KingDirectorMay 2018
Michael LaVern SorensenDirectorMay 2018
Richard LaVern MalcolmDirectorMay 2018
Roger LaVern DavenportDirectorMay 2018
Matt S. KingDirectorDec 2017
Phil S. WaughDirectorDec 2017
Richard S. MalcolmDirectorDec 2017
Todd S. FoleyDirectorDec 2017
Tony S. RosenbergDirectorDec 2017
Ansbert RS GadickeDirectorApr 2015
Brad RS GeesamanDirectorApr 2015
Douglas E. Pierce, Jr.DirectorApr 2015
Edward S. SeguineDirectorApr 2015
Matt RS KingDirectorApr 2015
Morana RS Jovan-EmbiricosDirectorApr 2015
Philip RS Waugh, Jr.DirectorApr 2015
Robert RS KniejskiDirectorApr 2015
Todd RS FoleyDirectorApr 2015
Robert H. KniejskiDirectorOct 2013
Stephen H. ColtrinDirectorOct 2013
Christopher H. RammDirectorDec 2011
Michael E. LesterDirectorDec 2011
Douglas E. Pierce, Jr.PromoterApr 2015
Edward S. SeguinePromoterApr 2015
Edward S. Seguine, Jr.PromoterDec 2011